OncoSec Medical - Developing and Commercializing Revolutionary Cancer Therapies
OncoSec Medical Inc (OTC BB: ONCS) is developing novel, localized anti-cancer therapies against solid tumors to overcome the significant cosmetic, functional and other side effects associated with surgery and other non-targeted therapeutic approaches.
Oncosec’s minimally invasive therapies use electrical stimulation known as electroporation to significantly increase the entry of anti-cancer chemotherapeutic or biologic agents into cells of selectively targeted tumors and tissue. These treatments selectively destroy cancer cells while preserving healthy tissue. They optimize required dosage and potentially reduce treatment and post-treatment costs.
OncoSec is advancing its novel anti-cancer therapies into advanced stage clinical trials.
Oncosec’s minimally invasive therapies use electrical stimulation known as electroporation to significantly increase the entry of anti-cancer chemotherapeutic or biologic agents into cells of selectively targeted tumors and tissue. These treatments selectively destroy cancer cells while preserving healthy tissue. They optimize required dosage and potentially reduce treatment and post-treatment costs.
OncoSec is advancing its novel anti-cancer therapies into advanced stage clinical trials.
Subscribe To Our Newsletter
Investor Presentation
Download OncoSec Medical's Corporate Profile Powerpoint